Generics Ibrahim Monchito, Deputy Executive Director of the Department of Science and Technology ICT Office stresses the need to bring higher value to the HIM industry as a means to protect the local industry and help companies grow. He further elaborates on a government point of view of the actions taken…
Generics David Goodman, CEO of Pharmascience, describes the importance of balancing innovation with low cost products in Canada and outlines his company’s strategy for growth domestically and internationally. 2013 marks the thirtieth anniversary of Pharmascience. How does the company’s original business compare with its business today? Pharmascience was first established as…
UAE Ashraf Allam, Regional Managing Director of Amgen, talks about the main challenges the company has faced, the benefit of building a company in the UAE, and the growth strategy of Amgen—past, present and future. Amgen is a relative newcomer to the region having only established is operations in 2006.…
Biotechnology Ashraf Allam, Regional Managing Director of Amgen, talks about the main challenges the company has faced, the benefit of building a company in the UAE, and the growth strategy of Amgen—past, present and future. Amgen is a relatively newcomer to the region having only established is operations in 2006. As…
Adimmune Corporation The president of Adimmune Corporation discusses how the avian flu outbreak of 2006/2007 changed the course of the drug manufacturing industry in Taiwan, what that meant for Adimmune, and how he plans to get Adimmune and the Taiwanese biotech industry on the map. Over the past few decades, how has…
Life Sciences The funding of Canada’s biotech industry has changed drastically in recent years. Peter Van Der Velden of Lumira Capital discusses those changes and how his venture capital business is adapting to this evolving environment. Lumira has been involved with numerous acquisitions over the years. Could you highlight a couple of…
CROs Riaz Bandali, President ESD of InVentiv Health Clinical discusses the ways in which the company’s unique combination of different technologies and capabilities will help lead the way to better healthcare and the ability to treat individuals more effectively. What was your initial mandate at InVentiv? Like many Canadian health and…
Biosimilars Audrey Tseng, Deputy Chairman of PwC Taiwan with PwC Partners Lily Wong and Andy Chang, delve into factors behind the booming pharma and biotech industry in Taiwan, how to prevent a bubble burst, and the crucial next steps in maintaining the momentum to continue growth within the industry. Please start…
Interface Biologics Tom Reeves of Interface Biologics (IBI) offers his input about the company’s roadmap towards commercialization, as well as IBI’s differentiation and the advantages of collaborating with international partners. You joined IBI in 2008, what was your initial mandate upon arriving here? My initial mandate was to demonstrate commercial viability. Since…
Investissement Québec Investissement Québec is a public corporation whose mission is to contribute to Québec’s economic development. Investissement Québec’s project manager, Stéphanie Murphy, discusses the role and contribution of pharmaceutical companies to Quebec’s economic landscape and the challenges associated with promoting Quebec as an attractive place for FDI. What are some of…
Charles River Charles River is the fifth largest CRO globally and the Canadian affiliate is the largest preclinical organization worldwide. Glenn Washer talks to us about the environment for contract research in Canada and the competitive advantages this offers the company in being able to provide a wide range of services. You…
See our Cookie Privacy Policy Here
